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Abstract
Transient neonatal diabetes mellitus 1 (TNDM1) is a 
rare genetic disorder representing with severe neonatal 
hyperglycaemia followed by remission within one and a 
half year and adolescent relapse with type 2 diabetes in 
half of the patients. Genetic defects in TNDM1 comprise 
uniparental isodisomy of chromosome 6, duplication 
of the minimal TNDM1 locus at 6q24, or relaxation 
of genomically imprinted ZAC1 /HYMAI . Whereas 
the function of HYMAI, a non-coding mRNA, is still 
unidentified, biochemical and molecular studies show 
that zinc finger protein 1 regulating apoptosis and cell 
cycle arrest (ZAC1) behaves as a factor with versatile 
transcriptional functions dependent on binding to specific 
GC-rich DNA motives and interconnected regulation of 
recruited coactivator activities. Genome-wide expression 
profiling enabled the isolation of a number of Zac1 
target genes known to regulate different aspects of 
β-cell function and peripheral insulin sensitivity. Among 
these, upregulation of Pparγ  and Tcf4  impairs insulin-
secretion and β-cell proliferation. Similarly, Zac1-
mediated upregulation of Socs3  may attenuate β-cell 
proliferation and survival by inhibition of growth factor 
signalling. Additionally, Zac1 directly represses Pac1 
and Rasgrf1  with roles in insulin secretion and β-cell 
proliferation. Collectively, concerted dysregulation of 
these target genes could contribute to the onset and 
course of TNDM1. Interestingly, Zac1 overexpression 
in β-cells spares the effects of stimulatory G-protein 
signaling on insulin secretion and raises the prospect for 
tailored treatments in relapsed TNDM1 patients. Overall, 
these results suggest that progress on the molecular 
and cellular foundations of monogenetic forms of 
diabetes can advance personalized therapy in addition 
to deepening the understanding of insulin and glucose 
metabolism in general.
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Core tip: Accidents of nature leading to rare genetic 
diseases can provide important insights into the molecular 
and cellular foundations of related common diseases. 
Various genetic anomalies at chromosome 6q24 manifest 
with life-threatening transient neonatal diabetes mellitus 
(TNDM1). All of these genetic defects share overexpress-
ion of the maternally imprinted transcriptional regulator 
ZAC1 . Genome-wide expression profiling identified a 
number of downstream target genes sharing a critical 
role in insulin secretion, β-cell proliferation, and survival. 
Importantly, Zac1 overexpression in β-cells spares the 
effects of G-protein signaling on insulin secretion opening 
the prospect for tailored therapy in TNDM1 patients.
Hoffmann A, Spengler D. Role of ZAC1 in transient neonatal 
diabetes mellitus and glucose metabolism. World J Biol 
Chem 2015; 6(3): 95-109  Available from: URL: http://www.
wjgnet.com/1949-8454/full/v6/i3/95.htm  DOI: http://dx.doi.
org/10.4331/wjbc.v6.i3.95
INTRODUCTION
The individual, societal, and economic burden of 
the diabetes epidemic has raised steadily over the 
last decades despite continuous refinements in die­
tary and pharmacological therapies[1]. On current 
trends, at least one in 10 people alive today are at 
risk to suffer from diabetes at some stage during 
their lifespan. At the same time, the total number 
of individuals being at risk to develop diabetes is 
predicted to double in a generation from 150 million 
in 2000 to 300 million by 2025. Existing medical 
treatments frequently ameliorate diabetic conditions 
without reinstating normal metabolism and thus 
leave many patients exposed to debilitating, or 
even life­threatening, impairments[2]. In conjunction 
with genetic predisposition (particularly in some 
ethnicities) the epidemic derives mainly from type 
2 diabetes (T2D) and associated conditions termed 
“diabesity” and “metabolic syndrome”. These states 
encompass various risk factors such as obesity, overly 
rich nutrition, and a sedentary lifestyle[3]. Although 
lifestyle modifications (balanced diet, more exercise, 
and weight reduction) are well­recognized to delay, or 
even prevent, T2D in persons at risk, such cautionary 
measures are notoriously hard to sustain[4].
A large number of epidemiological and experimental 
studies have aimed to detect the genetic and en­
vironmental factors underlying the onset, progression, 
and treatment response of diabetes over the last 
decades. Contrary to the well­established damage of 
insulin­producing β­cells by autoimmune processes in 
type 1 diabetes (T1D), the pathophysiological basis 
of T2D is still incompletely understood and involves 
multiple cellular and physiological systems influencing 
each other’s set points, thresholds, and metabolic 
functions[5]. Insulin resistance typically evolves during 
the course of T2D as result of a diminished sensitivity 
to insulin’s metabolic regulatory functions in several 
peripheral tissues (fat, muscle, and liver) aggravated by 
reduced exercise, aging, and obesity. T2D represents a 
relative, rather than an absolute insulin deficiency, as a 
result of a progressive malfunction of β­cells to secrete 
sufficient amounts of insulin for sustaining efficient 
carbohydrate and lipid homeostasis[6]. Conclusively, 
refined insight into the pathways that underlie β­cell 
dysfunction at a physiological and molecular scale 
remains desirable to advance personalized treatment of 
T2D. 
How can we examine human β­cells when these are 
barely accessible? Single gene defects encoding severe 
β­cell dysfunction with manifest diabetes provide 
unique inroads to disease mechanisms if the causative 
gene can be isolated. In this regard, positional cloning 
enabled the identification of heterozygous mutations 
in the hepatic transcription factors HNF1A and HNF4A 
as the cause of early­onset diabetes[7,8]. This important 
discovery drove forth the subsequent discovery of 
a transcription factor network underpinning normal 
β­cell development[9] as well as susceptibility to 
T2D[10,11]. Hence, monogenetic diseases can guide 
biological studies aimed to unlock the cellular and 
molecular basis of the specific condition under study, 
but may have also important implications for related 
multifactorial diseases.
Based on this perspective, we will discuss in this 
review recent progress in the molecular genetics 
of transient neonatal diabetes mellitus (TNDM) and 
how these new findings advance insight into β­cell 
development and physiology. Specifically, we will focus 
on the transcriptional regulator ZAC1 (zinc­finger 
protein 1 regulating apoptosis and cell cycle arrest), 
which is encoded by a genomically imprinted gene at 
6q24 in human. TNDM is characterized by a unique 
clinical course manifesting prenatally with T1D and an 
increased risk for T2D in adolescence. Importantly, 
the identification of various target genes over the last 
years eventually enabled insight into ZAC1’s role in 
pancreatic β­cell development and maturation and 
potential pharmacological treatments of newborns 
suffering from TNDM.
NEONATAL DIABETES MELLITUS
Neonatal diabetes mellitus (NDM), also recognized as 
“early­onset” diabetes mellitus, manifests unregulated 
hyperglycemia during the first 6 mo of life and is a rare 
disorder developing uniformly in all races and ethnic 
groups. Typically, NDM presents with intrauterine 
growth retardation (IUGR), reduced subcutaneous fat, 
failure to thrive, and low or undetectable C­peptide 
levels (a peptide of 31 amino acids connecting the 
A­chain and the B­chain of proinsulin)[12]. NDM com­
monly arises from mutations in genes that play a 
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crucial role in pancreas development, β­cell apoptosis, 
insulin processing, and the regulation of insulin 
release[13]. NDM has an incidence of 1 in 300000 to 
500000 live births, whereby current data indicate 
that approximately over half (57%) of the cases are 
transient (TNDM), depend on initial insulin application, 
and resolve spontaneously in less than one and a half 
year, only to relapse in adolescence. 
Different genetic defects have been identified as 
the source of TNDM; these include mutations in the 
potassium channel genes ABCC8 (TNDM2; OMIM 
310374) and KCNJ11 (TNDM3; OMIM 610582)[14], 
insulin[15], and occasionally HNF1B[16]. About two­third 
of all cases of TNDM derive from genetic mutations or 
loss of genomic imprinting at a locus on 6q24 (TNDM1; 
OMIM 603044)[13] encoding ZAC1 (alias PLAGL1), 
which is in the focus of the remainder of this review, 
and HYMAI (hydatiform mole associated and imprinted 
transcript) whose biological function remains unknown 
so far.
TNDM1
Clinical picture and course
TNDM1 was firstly described as a clinical entity in 1926[17]. 
Similar to NDM, newborns suffering from TNDM1 
represent with perinatal hyperglycemia, undetectable 
or very low insulin levels, and severe dehydration. 
Altogether, this life threatening condition requires 
immediate insulin therapy. IUGR develops in > 95% of 
TNDM1 cases during the third trimester and concurs 
with severely reduced subcutaneous fat formation in 
neonates[18]. Consistent with insulin’s hypothesized role in 
growth stimulation, postnatal substitution initiates a fast 
catch­up growth and normalizes TNDM1 patients’ height 
and weight by the age of 2 years. 
Additionally, TNDM1 patients can display a number 
of symptoms varying in penetrance and unrelated 
to diabetes such as macroglossia, umbilical hernia, 
cardiac anomalies, brain malformation, and mental 
impairments in lately diagnosed newborns. These 
features are shared among TNDM1 infants irrespective 
of the underlying genetic anomalies[18]. 
It is important to note, that insulin dependency 
declines within a few months postnatally (median 
treatment duration 3 mo) and rarely extends for up to 
one and a half year. Following on, TNDM1 remits and 
patients represent as normoglycemic, free of glycemic 
compromise, and sustain normal growth[19]. This 
reversible course seems compatible with a temporary 
rather than a persistent defect in the control of insulin 
synthesis and/or secretion. Yet, approximately one 
half of all TNDM1 patients develop in adolescence or 
early adulthood signs of T2D[20] and require dietetic as 
well as pharmacological treatments (sulfonylurea and 
insulin) to ameliorate hyperglycemia. Puberty­related 
hormonal changes and resumption of somatic growth 
are known to impose an increased demand on insulin’s 
availability, may compromise pancreatic functions, and 
ultimately, lead to relapse with T2D in persons at risk. 
Alternatively, the same genetic defect underlying 
impaired insulin secretion, and consequently IUGR, 
may predispose to relapse in later life[21]. Epigenetic 
mechanisms, particularly DNA­methylation, are thought 
to mediate epigenetic programming in response to early 
life conditions[22,23] and are increasingly recognized to 
interact with genetic risk factors.
Collectively, TNDM1 represents with neonatal hyper­
glycemia, infant remission, and adolescent relapse. IUGR 
and hyperglycemia suggest a decline in available insulin 
due to a deficit in β­cell number and/or compromised 
insulin secretion.
Molecular and clinical genetics of TNDM1
Paternal uniparental disomy of chromosome 6 (UPD6) 
was firstly discovered in two TNDM1 patients in 1995[24]. 
The same report presciently suggested that TNDM1 is 
a genomic imprinting disorder[25] ­ a hypothesis that 
has been confirmed as early as five years later[26,27]. 
Expression at the TNDM1 locus on chromosome 6q24 
is confined to the paternally derived allele with the 
maternal allele being silenced. This process, termed 
genomic imprinting, is initiated in the respective parental 
germ cells and involves DNA methylation as a central 
mechanism[28]. As a result, the expressed paternal 
ZAC1 allele is unmethylated at a confined region of 1 
kb in size, the so called differentially methylated region 
(DMR), while the silenced maternal allele is methylated. 
The DMR straddles the shared promoter of ZAC1 and 
HYMAI establishing monoallelic expression in healthy 
individuals. Contrarily, a defect in DMR methylation 
results in relaxation of ZAC1/HYMAI imprinting with 
biallelic expression in TNDM1[29]. Although it has not 
been formally proven whether one or both of these 
genes underlie TNDM1, it appears decent to assign a 
critical role to ZAC1 based on its molecular and cellular 
properties (see below). In contrast, the non­coding RNA 
HYMAI is transcribed from the same imprinted promoter 
and in the same orientation as ZAC1 and is ubiquitously 
expressed throughout development and maturation 
although its function remains still unresolved[27,30]. 
Notwithstanding the limited information on HYMAI, 
further studies are looked for with respect to the critical 
role of non­coding RNAs in the control of imprinted gene 
expression[28].
In addition to the proximal promoter, ZAC1 contains 
a second promoter some 50 kb upstream, which is 
devoid of genomic imprinting, drives biallelic ZAC1 
expression, and predominates in blood cells[31]. Although 
biallelic expression may prevail in some tissues or 
across defined periods, monoallelic expression from 
the imprinted promoter is preserved during mouse 
development and seems to fulfil a particular role in 
tissues regulating glucose metabolism and/or showing 
dynamic changes in perinatal Zac1 expression (see 
below). Still, the possibility of postnatal switches in 
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the inheritance in human, hyperglycemia in neonate 
mice was confined to offspring derived from paternal 
transmission of the overexpressed PAC. 
Interestingly, the effects from ZAC1 overexpression 
in mice largely recapitulated human TNDM1 with 
neonate hyperglycemia, juvenile remission, and adult 
glucose intolerance[40]. Yet, neonate growth was not 
retarded at birth nor were aged mice overt diabetic. 
Histological examination of pancreata from TNDM1 
mice suggested a reduction in the development and 
existence of all endocrine cell types including β­cells 
concomitantly with a downregulation of the important 
developmental transcription factors Ngn3, Pax6, and 
Pdx1. Puzzlingly, in late pregnancy and postnatally 
transgenic β­cells assumed a rapid catch­up growth 
as a result of increased proliferation and/or decreased 
apoptosis and surpassed in numbers their normal 
counterparts. Irrespective of this increase in neonatal 
β­cell numbers, insulin content and secretion were 
diminished and resulted in postnatal hyperglycemia. 
Still, an ongoing increase in β­cell numbers enabled 
their duplication and reinstatement of normal glucose 
tolerance in juvenile mice. This compensatory increase 
was, however, not sustained in aged mice, which 
suffered from an accelerated decline in β­cell numbers 
and compromised insulin secretory capacity when 
compared to controls. 
Together, these findings in mice corroborate ZAC1/
HYMAI’s maternal imprinting status and evidence the 
impact of these genes on pancreatic β­cell proliferation, 
differentiation, and insulin secretion from late gestation 
through adulthood. Consistent with these data, ZAC1 
overexpression in rodent β­cell lines[41,42] reduces 
glucose­stimulated insulin secretion (GSIS) as will be 
discussed in more detail in the section on target genes. 
In contrast to ZAC1 overexpression in pancreatic 
β­cells, results from Zac1 deficient mice (Zac1+/-pat) 
evidenced no obvious effects on β­cell proliferation or 
insulin secretion[43]. Zac1+/-pat mice represented with 
IUGR, altered bone formation, impaired pulmonary 
respiration, hydrocephaly, disturbed neural cell numbers, 
and neonatal lethality[43,44]. Notably the same authors[43] 
assigned to Zac1 a critical role in the regulation of an 
IGN, which on its own may affect β­cell function and 
confound Zac1 defects. 
All in all, these studies support a role of ZAC1 
overexpression in TNDM1 and prompt the question 
through which molecular and cellular mechanisms 
ZAC1 contributes to the clinical picture and course of 
TNDM1.
TRANSCRIPTIONAL REGULATOR ZAC1
The zinc-finger protein Zac1 was originally isolated from 
clonal corticotroph tumor cells derived from mice[45] and 
shortly afterwards from malignantly transformed ovary 
surface epithelial cells[46]. Zac1 overexpression studies 
together with appropriate knock­down experiments 
promoter usage[32] during postnatal remission and/or 
relapse with T2D should not dismissed and requires 
further analysis.  
Although half of the TNDM1 patients relapse with 
T2D in early adulthood, ZAC1 seems not to encode a 
T2D susceptibility locus. Whereas the chromosomal 
region 6q22­25 has been initially captured in some 
genome­wide association studies, particularly in the 
Pima Indian population[33], this finding was refuted in 
a recent large case­control study in which not a single 
ZAC1 nucleotide polymorphism (SNP) associated with 
T2D[34]. This study lacked however sufficient power to 
address a parental impact on SNP effects ­ an important 
issue since investigations in the Iceland population 
evidenced several imprinted loci among regions with a 
disease association dependent on parental origin[35]. 
In addition to the original discovery of UPD6, dupli­
cation of the TNDM1 region, and maternal hypomethy­
lation at the DMR have been identified subsequently as 
a genetic cause of TNDM1[36].  
Children suffering from UPD6 (40%) can display 
additional symptoms unmasked by uniparental disomy 
(e.g., recessive mutations). Since UPD6 is the result of 
a stochastic reproductive error, it is non­hereditary. In 
contrast, duplication of 6q in TNDM1 patients (32%) 
comprises a critical region of approximately 160 kb 
and can be passed to offspring with manifestation 
in males[37]. The majority of these duplications are 
submicroscopic, differ in breakpoints, but share a 
similar phenotype[36]. 
Hypomethylation at the DMR in TNDM1 patients 
(28%) leads to erasure of all maternal methylated CpG 
residues and suggests that normal ZAC1 gene dosage 
has to be severely disrupted to manifest TNDM1. 
It is important to note, that approximately 50% of 
TNDM1 patients with ZAC1 DMR hypomethylation 
suffer from hypomethylation at other imprinted loci as 
well[38]. This raises the possibility that defects in the 
imprinting machinery (e.g., loss of ZFP57, a zinc-finger 
transcription factor containing a KRAB domain[39]) 
or imprinted gene networks (IGN) can give rise to 
TNDM1[32].
In sum, TNDM1 patients show genetic defects 
leading to overexpression of ZAC1 from the imprinted 
region of chromosome 6q24. The underlying chro­
mosomal anomalies comprise paternal UPD6, paternally 
derived duplication of 6q24, and maternal methylation 
defects at the DMR[20,29]. 
TRANSGENIC MOUSE MODELS OF 
TNDM1
ZAC1 overexpression in TNDM1 stimulated the creation 
of suitable mouse models to analyze the underlying 
pathology. For this purpose, a P1­derived artificial 
chromosome (PAC) of 175 kb comprising the entire 
ZAC1 and HYMAI loci was integrated with multiple 
copies into the mouse genome[40]. In accord with 
Hoffmann A et al . ZAC1 and TNDM1
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evidenced Zac1’s role in the regulation of apoptosis and 
cell cycle arrest and stimulated its name­giving[45,47,48]. 
In agreement with these observations, human ZAC1[48], 
undergoes methylation­sensitive silencing in various 
tumors including ovary and mammary cancer[46,49].
Human and mouse ZAC1 proteins consist of 463 
and 693 amino acids, respectively, and share a highly 
conserved amino­terminal DNA­binding domain 
enclosing seven zinc fingers conforming with the 
classical C2H2­type (Figure 1A). Apart from that, a 
central and C­terminal domain enriched in proline 
and glutamic acid residues, respectively, exists solely 
in mice[48]. The region adjacent to the DNA­binding 
domain, termed linker­region, together with the 
central proline­rich region confers transactivation in 
mice, which is enhanced by the C­terminus’ interaction 
with the general coactivators p300/CBP[50]. On the 
other side, transactivation and coactivator recruitment 
are merged in ZAC1’s C­terminus and illustrate how 
different protein motives are used species-specifically 
in transactivation (Figure 1A). 
Monomeric Zac1 can bind to palindromic GC­rich 
DNA elements to confer transactivation (Figure 1B). 
Similarly, Zac1 dimerization at direct and reverse G/
C­rich repeat DNA elements confers transactivation 
whereas monomeric binding to single half sites leads to 
repression[51] (Figure 1B). In addition to DNA binding, 
zinc finger 6 and 7 interact with p300 to increase 
(palindromes and repeats) or decrease (half sites) its 
catalytic activities[50]. This interrelationship between 
Zac1’s DNA address code and enzymatic regulation of 
transcription is thought to support efficient regulation 
of target genes.
Moreover, Zac1 can coregulate the activity of 
various members of the nuclear receptor and p53 
families without binding on its own to DNA due to 
its scaffolding function and concomitant coactivator 
regulation[52­54] (Figure 1C). The p53 family comprises 
the eponym p53 and the relatives p63 and p73, 
all of which share critical roles in cell renewal and 
proliferation, cell fate commitment and differentiation, 
and ultimately apoptosis[55]. As an example, the 
transcription factor p73 tethers the coactivators PCAF/
p300 and Zac1 jointly to the p21Cip1 (Cdkn1a) promoter 
in a model of early neuronal differentiation. Consistent 
with its scaffolding function Zac1 strengthens via its 
zinc fingers the interaction between PCAF and p300 
and enhances at the same time PCAF’s catalytic 
activity (Figure 1C)[52]. This finding evidences an 
authentic Zac1 coactivator function and suggests that 
similar mechanisms apply to Zac1­dependent nuclear 
receptor coregulation[53]. 
In summary, Zac1 transcription factor activities 
are determined by sequence­specific DNA binding 
and interconnected regulation of coactivator activities. 
Additionally, Zac1 can act as coregulator for unrelated 
transcription factors by stabilizing complex formation 
with recruited coactivators and enhancement of their 
catalytic functions.
ZAC1 TARGET GENES IN THE PANCREAS 
Zac1’s role as transcription factor and coregulator offers 
the opportunity to gain insight into its function in TNDM1 
via the identification of downstream target genes. In the 
context of this review we will pay particular attention 
to those targets, which are expressed in pancreatic 
β­cell islets and are likely to share a role in insulin and 
glucose metabolism. Readers interested in further Zac1 
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Figure 1  Transcriptional activities of Zac1. A: Schematic drawing of Zac1 
proteins. Domains are boxed and numbers refer to amino acids and percentage 
of homology between mouse and human. The N-terminal DNA binding domain 
is highly conserved between human and mice and comprises seven canonical 
C2H2-type zinc fingers (ZF). The linker domain (L) in conjunction with the 
proline-rich region (PR) confers transactivation in mice, which is further 
enhanced through the C-terminus’s coactivator binding (CB) domain. Contrarily, 
transactivation and coactivator recruitment jointly localize to ZAC1’s C-terminus; 
B: Zac1 recognizes different DNA-elements to confer transcriptional regulation. 
Monomeric Zac1 binding to GC-rich palindromes (left) or dimerization at G/C 
rich direct repeat elements (middle) results in transactivation. On the other 
hand, monomeric Zac1 binding to G/C rich half sites causes repression (right); 
C: Zac1 coactivation of p73. Following recognition of its DNA-binding site (DBS), 
the transcription factor p73 recruits Zac1 together with the general coactivator 
p300 and PCAF to the p21Cip1 promoter during early neural differentiation. 
Due to its scaffolding function, Zac1’s zinc fingers stabilize this interaction and 
enhance additionally PCAF’s histone acetyltransferase (HAT) activity. This 
event enhances histone acetylation at the p21Cip1 promoter and subsequent 
transcription.   
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In support of ZAC1’s potential role in TNDM1, strong 
immunoreactive signals were detected in the nuclei of 
insulin positive cells, whereas the exocrine pancreas 
was only sparsely stained in adult human[42]. Refined 
immunohistochemistry in mice evidenced strong Zac1 
signals at prenatal and neonatal stages [(embryonic 
day 18 (E18) and postnatal day 1 (P1)] in the endocrine 
pancreas of both insulin­expressing and non­expressing 
cells. Moreover, sparse immunoreactivity was spread 
throughout the exocrine pancreas. Postnatally, Zac1 
immunoreactivity rapidly declined in either pancreas 
compartment (P4 to P12) in accord with previous 
reports[40,57]. Subsequently, Zac1 expression was 
maintained at lower levels in insulin­positive cells in 
early adult mice (P42) but was largely absent in the 
parenchyma consistent with the findings in human[42]. 
Together, these findings corroborate ZAC1 exp­
ression in insulin­positive cells in human and mice and 
reveal dynamic changes in perinatal expression levels.
PAC1
PAC1 (alias ADCYAP1R1) encodes a G­protein coupled 
receptor (GPCR) for the neuropeptide pituitary ad­
enylate cyclase activating polypeptide (PACAP) and 
was the first Zac1 target gene to be identified[45,58,59]. 
Zac1 regulates Pac1 gene expression and related 
promoter reporter constructs in a cell type­specific 
fashion as evidenced by activation in cerebellar granule 
cells, epithelial kidney cells, and osteosarcoma cells vs 
inhibition in pituitary gonadotroph cells and pancreatic 
β­cells[58,60,61] (Hoffmann A, Spengler D. Unpublished 
findings. 2012). The neuropeptide PACAP was firstly 
purified from sheep hypothalamus[62] and has multiple 
functions on the neuroendocrine, endocrine, and 
nervous system[63]. Pancreatic islets are richly innervated 
via pancreatic ganglia that derive from the vagus dorsal 
motor nucleus. Both ganglia and islets contain PACAP as 
well as the related vasointestinal peptide (VIP) among 
other neurotransmitters. This distribution suggests that 
PACAP can act at the same time as neurotransmitter 
and islet endocrine peptide[64]. 
The VIP/PACAP receptor family comprises PAC1 
(specific for PACAP), VPAC1, and VPAC2 (both with 
equal affinity for VIP and PACAP)[65]. Pancreatic 
islets express all of these receptors, which couple to 
stimulation of adenylate cyclase[66,67]. Increases in 
intracellular levels of cAMP activate protein kinase A 
(PKA) and guanine nucleotide exchange factors of the 
Epac family that enhance insulin secretion through 
distinct pathways involving KATP channels together with 
the exocytotic machinery[68]. 
Intracellular glucose metabolism presents the 
major stimulus for GSIS. This process commences 
with the uptake of glucose into β­cells via the glu­
cose transporter protein 2 (Glut­2). Breakdown of 
glucose leads to ATP production and an enhanced 
ATP/ADP ratio followed by closing of KATP channels. 
Subsequently, plasma membrane depolarization and 
Ca2+ influx stimulate the exocytosis of insulin. 
PACAP and VIP are thought to potentiate glucose­
stimulated, but barely resting, insulin secretion by 
increasing intracellular Ca2+ concentrations[64]. In 
accord with this hypothesis, Pac1 null mice develop 
apparently normal and represent with inconspicuous 
resting plasma glucose and insulin levels[69]. On 
the other side, the response to PACAP on GSIS 
was reduced by half in isolated islets from Pac1 null 
mice. Moreover, these mice showed reduced GSIS 
following intravenous or oral glucose administration. 
Hence, Pac1 seems to control the insulin­secretory 
response to insulin itself in addition to its potentiation. 
Consistent with this possibility, Pac1 null islets showed 
a diminished insulin response to glucose indicating Pac1’s 
critical role for optimal GSIS during food intake[69]. A 
possible explanation for this finding is that intracellular 
PACAP, independently of neural release, triggers PKA 
activation necessary for optimal calcium influx in the 
context of GSIS.
In contrast to PACAP’s role for insulin secretion, 
its effects on long­term β­cell mass have been less 
studied. Islets commonly decline during the course 
of T2D and aggravate the increased demand for 
insulin. Interestingly, PACAP overexpression in β­cells 
ameliorated the effects of streptozotocin­induced cell 
death as evidenced by lower plasma glucose levels 
in transgenic mice when compared to controls[70]. 
Morphometric analysis showed a tendency towards 
increased β­cell mass suggestive of a role for PACAP in 
the regulation of islet cell proliferation or differentiation. 
Compatible with this view, PACAP enhances the growth 
of pancreatic cancer cells through cAMP/PKA­dependent 
stimulation of the MAP kinase pathway together with 
the upregulation of nuclear oncogenes[71]. Relatedly, 
other studies suggest that intracellular PACAP protects 
β­cell mass by preventing harmful exogenous insults on 
the β­cell[72,73]. 
All in all, these studies raise the possibility that 
altered ZAC1 dosage in TNDM1 reduces PAC1 expression 
in β­cells, GSIS, the insulin­secretory response itself, and 
β­cell proliferation or survival on the long term. 
PPARγ
Genome­wide expression analysis[74] led to the iden­
tification of Pparγ (peroxisome proliferator­activated 
receptor) as a Zac1 target gene. PPARγ belongs to the 
nuclear hormone receptor family with an important 
function in adipogenesis, lipid and glucose metabo­
lism, differentiation, antiproliferation, apoptosis, and 
inflammation[75]. The 5’end of PPARγ is subject to al­
ternative splicing that produces two protein isoforms 
differing in 30 amino acids present in the PPARγ2, 
but absent in the PPARγ1, amino terminus[76]. PPARγ2 
expression prevails in adipose tissue, whereas PPARγ1 
is more widely expressed comprising heart and skeletal 
muscle, kidney, liver, spleen, colon, pituitary, brain, 
and pancreas. ZAC1 binds in vitro and in vivo to the 
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proximal promoter region of PPARγ1 in various cell 
types (neural cells, pituitary cells, and colon cells among 
others) derived from rodent or men[74]. Functionally, 
ZAC1 antiproliferation partly depends on PPARγ1 
expression and associates with the upregulation of 
PPARγ target genes contributing to differentiation (KER20 
and TSC22), apoptosis (POX) or growth inhibition 
(PTEN). 
Notably, PPARγ overexpression has been suggested 
to attenuate glucose­ and potassium­induced sti­
mulated insulin secretion[77,78]. This effect is thought to 
relate to PPARγ’s upregulation of uncoupling protein­2 
(UCP­2), which reduces the availability of ATP needed 
for the energy­consuming exocytotic process of insulin 
secretion. 
On the contrary, β­cell specific deletion of Pparγ 
causes islet hyperplasia with unaltered glucose homeo­
stasis[75]. A plausible Pparγ target gene contributing to 
these effects is Pten (phosphatase and tensin homologue 
deleted on chromosome 10), which diminishes in­
tracellular levels of phosphatidylinositol via inhibition 
of phosphatidylinositol­3­kinase (PI3K). As a result, 
deletion of Pten enhances cell proliferation and survival 
without disrupting differentiation[79]. 
Interestingly, Pten’s effects on β­cell proliferation 
extend to models of T2D and deteriorated insulin 
secretion in aged mice. In this regard, continuous 
β­cell specific deletion of Pten protects against T2D 
ensuing from high-fat diet or deficient leptin-signaling 
due to a gain in β­cell mass under basal and diabetic 
circumstances[80]. Similarly, a knockout of Pten at 
adult age manifests an enhanced β­cell mass and 
proliferation as result of a sustained response to 
mitogenic stimulation during aging[81].  
In summary, these findings support that enhanced 
ZAC1 expression may impair insulin secretion and β­cell 
proliferation via induction of PPARγ and its downstream 
targets UCP-2 and PTEN. Because this pathway has 
not formally been proven to exist in pancreatic β­cells, 
further studies on this transcriptional network are 
looked for.      
Rasgrf1
The small G­protein Ras integrates multiple upstream 
signaling pathways and connects them to different 
downstream effectors comprising the Raf­MEK­Erk 
kinase cascade, the PI3K­Akt pathway, and RalGDS 
family members among others[82]. Ras alternates 
between an active GTP­bound and inactive GDP­bound 
state. This balance is tightly regulated by GTPase­
activating proteins (GAPs) and guanine nucleotide­
exchange factors (GEFs), respectively. Various GEF 
proteins have been isolated; among these RAS 
protein­specific guanine nucleotide­releasing factor 
1 (RASGRF1) and RASGRF2 are stimulated by the 
G­protein subunits β and γ or by calmodulin­mediated 
Ca2+ influxes (Figure 2). 
Genome­wide expression profiling for Zac1 target 
genes in neural cells evidenced downregulation of 
Rasgrf1[74]. Originally thought to be confined to postnatal 
brain, Rasgrf1 expression has been also detected 
in adult mice islets[83]. Consistent with this report, 
cytoplasmatic RASGRF1 expression colocalizes with 
nuclear ZAC1 expression in adult human insulin­positive 
cells with weak expression in the parenchyma[42]. A 
similar expression pattern exists in mice with Rasgrf1 
and Zac1 mRNA and protein expression correlating 
inversely with each other pre­ and postnatally. Ac­
cordingly, Rasgrf1 was weakly expressed at E18 when 
Zac1 expression is high and rapidly increased postnatally 
when Zac1 expression declined. Expression of both 
Zac1 and Rasgrf1 in two mouse β­cell models (Min6 
and R7T1) was similar to P4 neonate islets from mice 
with a strong decrease of Rasgrf1 expression following 
Zac1 transfection. Chromatin­immunoprecipitation 
(ChIP) analysis evidenced that Zac1 bound at multiple 



















Figure 2  Roles for RAS protein-specific guanine nucleotide-releasing 
factor 1 in insulin secretion and transient neonatal diabetes mellitus type 
1. Glucose is the main stimulus for insulin secretion. Once transported into 
pancreatic β-cells by glucose transporter 2 (GLUT2), metabolisation of glucose 
results in the production of ATP. A subsequent rise in the ATP:ADP ratio drives 
closure of ATP-regulated K+ channels and accumulation of intracellular K+. 
Heightened K+ concentrations lead to depolarization of the plasma membrane 
and promote opening of voltage-dependent Ca2+ channels with subsequent 
influx of Ca2+ and increases in free cytoplasmatic Ca2+. This event stimulates 
exocytosis of insulin from the insulin-storing secretory granules through different 
routes including activation of the Ca2+-calmodulin activated RAS protein-
specific guanine nucleotide-releasing factor 1 (RASGRF1), a direct ZAC1 target 
gene. In its activated state the small G-protein RAS couples to ERK1/2 and 
PI3K/AKT signaling among other downstream effectors, which jointly enhance 
the exocytotic process of insulin secretion. ZAC1 overexpression in transient 
neonatal diabetes mellitus type 1 (TNDM1) is predicted to directly repress 
RASGRF1 and consequently GSIS. Contrarily, PKA signaling is undisturbed in 
TNDM1 as well as the potentiating effects of the GLP-1R agonist liraglutide on 
GSIS.  
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and associated with the presence of repressive histone 
marks[42]. 
R7T1 β­cells were stably transfected to express 
double amounts of Zac1 as an in vitro model to simulate 
the effects of biallelic ZAC1 expression in TNDM1. 
Zac1 overexpressing β­cells showed moderately de­
layed differentiation with unaltered cell proliferation. 
Importantly, Zac1 overexpression impaired glucose­, 
insulin­, and potassium­induced depolarization and 
the subsequent activation of MAPK and PI3K pathways 
driving insulin secretion (Figure 2). Consistent with a 
crucial function of Rasgrf1 in Zac1­dependent insulin 
secretion, reinstatement of Rasgrf1 expression in 
Zac1 overexpressing R7T1 β­cells normalized insulin 
secretion[42]. Moreover, subcutaneous transplantation 
of parent, but not of Zac1 overexpressing R7T1 β­cells 
ameliorated hyperglycemia in streptozotocin­treated 
diabetic mice. 
Notably, activated Ras may additionally switch on 
the GEF function of RalGEF and Tiam1. Hereby, Tiam1 
facilitates the action of Rac1 with a regulatory role in 
GSIS[84] and RalGEF enhances the activity of the small 
G­protein Ral with a regulatory role in different steps 
of insulin exocytosis[85,86]. Hence, Zac1­dependent 
Rasgrf1 repression may integrate additional pathways 
beyond canonical MAPK and PI3K signaling, which 
overall result in an impaired GSIS.  
Activation of GPCRs leading to an increase in 
intracellular levels of cAMP (see above), are known to 
optimize the insulinotropic effects of glucose. In this 
regard, the glucagon­like peptide 1 receptor (GLP­
1R) stimulates insulin secretion independent of Ras 
pathways. Indeed, liraglutide, a clinically used GLP­1 
analog, undistinguishably stimulated MAPK and PI3K 
pathways and downstream insulin secretion in stable 
mock­ and Zac1­tranfected R7T1 β­cells and strongly 
reduced hyperglycemia following their subcutaneous 
transplantation in experimental diabetic mice. 
Interestingly, the oral or intravenous glucose to­
lerance tests display a subnormal insulin response in 
adolescent TNDM1 patients whilst glucagon­stimulated 
insulin secretion is preserved[87]. Hence, β­cells in TNDM1 
patients seem to sustain the capability to secrete insulin 
in response to stimulatory GPCR pathways, but not to 
glucose stimulation. 
In summary, this work evidences a critical role for the 
regulatory Ras/Rasgrf1 dyad in GSIS. Zac1­dependent 
repression of Rasgrf1 diminishes the activation of Ras’ 
downstream effectors comprising canonical and non­
canonical pathways in insulin secretion. On the contrary, 
GPCR’s capability to potentiate GSIS seems to be spared 
from Zac1 overexpression in accord with findings from 
adolescent TNDM1 patients (Figure 2). 
Socs3
The neural stem cell line (C17.2) has been used for 
additional genome­wide expression profiling and led 
to the identification of Socs3 (suppressor of cytokine 
signaling) as potential Zac1 target gene[88]. SOCS 
proteins comprise a group of eight members (SOCS1 
through SOCS7 and CIS) all of which encompass a 
COOH­terminal SOCS box and a characteristic central 
Src homology­2 (SH2) domain. Cytokine stimulation 
leads to the activation and nuclear translocation of 
the signal transducer and activator of transcription 
(STAT) proteins that in turn upregulate the expression 
of SOCS genes among others. These transcription 
factors recognize their DNA address code at regulatory 
regions of the SOCS genes, and once induced, CIS, 
SOCS1, SOCS2, and SOCS3 form a canonical negative 
feedback loop that serves to attenuate further cytokine 
signaling[89]. Similarly, SOCS family members might 
also inhibit tyrosine kinase signaling, particularly by 
the insulin­like growth factor­1 (IGF­1) and insulin 
receptors (see below). 
The Socs3 gene contains multiple predicted Zac1 
DNA­binding sites clustered at the regulatory upstream 
region and the neighboring first intron. Complementary 
experiments including different Socs3 promoter reporter 
assays in conjunction with various Zac1 expression 
constructs as well as ChIP studies evidenced that 
Zac1 confers transactivation in an additive manner 
following binding to the Socs3 promoter and first intron. 
Similarly, ZAC1 potently induced SOCS3 in human 
neuroblastoma cells indicating that regulation of this 
target gene is preserved in human cells[88]. Functionally, 
Zac1 transiently induces Socs3 in NSCs during the 
course of astroglial, but not of neural, differentiation. 
Zac1­dependent Socs3 expression peaks at the astrog­
lial transition to maturation and has been suggested 
to prevent precocious astroglial differentiation by 
inhibition of related signaling pathways independent 
of Zac1’s cell cycle arrest function. In accord with this 
hypothesis, Zac1 knock­down advanced astroglial 
differentiation. Conversely, knock­down of Socs3 in 
Zac1 overexpressing cells reinstated timely astroglial 
differentiation irrespective of a Zac1­driven sustained 
G1 arrest. 
In sum, Zac1 transactivates in a lineage­specific 
manner Socs3 in NSCs and thus fine tunes astroglial 
differentiation independent of Zac1’s cell cycle ar­
rest function[88]. Moreover, these findings raise the 
possibility of a Zac1 role for Socs3 regulation in 
TNDM1, particularly in pancreatic islets. Although there 
are no experimental data available yet, we will discuss 
in the following part the rationale for future studies to 
explore this topic.
Originally viewed as negative regulators of cytokine 
signaling, SOCS proteins have been more recently also 
suggested to attenuate insulin receptor signaling[90]. 
Contrarily to cytokine receptors, insulin and IGF­1 
receptors contain tyrosine kinase activity on their 
own. Once bound by its receptor, insulin triggers 
autophosphorylation and catalytic activation leading 
to the phosphorylation of various intracellular targets, 
including insulin receptor substrate (IRS) proteins. In 
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their phosphorylated state, IRSs associate with multiple 
SH2 domain­containing proteins and enable that 
multiple signaling proteins are subsequently recruited 
to the plasma membrane where they regulate various 
signal transduction pathways controlling translocation 
of glucose transporters from intracellular vesicles to the 
plasma membrane, protein and glycogen synthesis, 
and ultimately cell proliferation and survival[90].     
Insulin resistance denotes an impaired tissue res­
ponse to insulin and presents an important pathogenic 
determinant in the manifestation of T2D. Heightened 
concentrations of proinflammatory cytokines comprising 
tumor necrosis factor­a (TNFa), interleukins (IL­1β and 
IL­6), and growth hormone (GH) during injury, obesity, 
or infection, are considered to advance the onset of 
insulin resistance in peripheral tissues[6]. In this context 
it is important to note that SOCS1 and SOCS3 proteins 
have been shown to disrupt signaling complex formation 
at insulin or IGF­1 receptors as a result of an enhanced 
degradation of the adaptor proteins IRS­1 and IRS­2. 
Consequently, insulin signaling declines in disease­
relevant organs such as liver and muscle as well as in 
adipose tissue[90]. Because both ZAC1 and SOCS3 are 
expressed in these tissues, ZAC1 overexpression in 
TNDM1 patients may contribute to relapse with T2D 
in adults via sustained upregulation of SOCS3 and 
subsequent impairments in insulin signaling. 
In addition to an effect on peripheral insulin sig­
naling, SOCS3 appears also to affect pancreatic β­cells 
themselves[91]. Tyrosine phosphorylation of the insulin 
receptor and associated IRS proteins in response to 
insulin binding is inhibited by IL­1β via upregulation 
of SOCS3 expression and the formation of SOCS3/
insulin receptor complexes. Together, these events 
result in reduced PI3K signaling and impaired long 
term survival of β­cells[91]. Relatedly, SOCS3 has been 
reported to attenuate growth factor signaling important 
to β­cell proliferation and cell mass[92]. In this respect, 
overexpression of SOCS3 exclusively in β­cells caused 
a reduction in β­cell volume by one third in transgenic 
mice and reduced STAT5 phosphorylation upon GH 
treatment of transgenic islets when compared to wild­
type ones. Similar results were obtained for adenovirus 
mediated SOCS3 overexpression in primary islets. 
Notably, SOCS3 overexpression spared the effects 
of GLP­1, mediated by PKA, on cell proliferation. 
Collectively, these results suggest that SOCS3 inhibits 
β­cell proliferation by counteracting growth factor 
receptor signaling.  
On the other side, a number of reports evidenced 
for SOCS3 a role in β­cell survival following exposure 
to cytotoxic factors. As far back as 2001, Socs3 has 
been suggested to protect against interferon­γ and IL­
1β­mediated β­cell damage by reduced transcription 
of inducible nitric oxide synthase (iNOS)[93]. Similarly, 
TNFa­induced apoptosis with a possible role in T1D 
is prevented by Socs3 overexpression in rat INS 
β­cells[94]. In further support of these findings, ciliary 
neurotrophic factor signaling (CNTF) increased STAT3 
(cytoplasmatic and nuclear phosphorylated forms) 
as well as Socs3 expression and protected against 
cytokine­ or streptozotocin­induced apoptosis[95,96]. At 
the same time, increased Socs3 expression impaired 
GSIS in isolated rat neonatal islets. 
Collectively, these results suggest that the effects 
from SOCS3 expression are context­dependent involving 
growth inhibition as well as improved survival following 
cytotoxic insults. 
Overall, ZAC1­dependent SOCS3 upregulation 
may contribute to different aspects in TNDM1 by: (1) 
facilitating development of peripheral insulin resistance 
in adults; (2) inhibiting prenatal β­cell proliferation; 
and (3) impairing GSIS. Future experimental studies 
are looked for to address these topics.
p57Kip2
The cyclin­dependent kinase inhibitor (CKI) p57KIP2 
fulfils a critical task in cell cycle progression and 
differentiation[97]. Cyclin­dependent kinases (CDK) 
represent an evolutionary conserved group of serine/
threonine kinases whose catalytic activities are tightly 
controlled through the association with various cyclins. 
The expression levels of cyclins oscillate periodically 
across the cell cycle and stimulate the sequential 
formation of different CDK­cyclin complexes that drive 
the coordinate progression through the cell cycle. 
Application of the neuropeptide PACAP (see above) 
rapidly increases p57Kip2 expression in embryonic 
cortical precursors and reduces the activity of CDK2, 
entry into S­phase, and the synthesis of DNA. At the 
same time PACAP enhanced the association of p57Kip2, 
but not of p21Cip1 or p27Kip1, with the kinase complex in 
accord with PACAP’s antimitogenic function[98]. Hence, 
Zac1­dependent induction of Pac1 in neural cells, but 
not in β­cells where Pac1 is repressed, may contribute 
via enhanced p57Kip2 expression to antiproliferation. 
Relatedly, Zac1 can induce p57Kip2 via an alternative 
route involving the basic helix­loop­helix (bHLH) protein 
Tcf4. The family of bHLH proteins coordinate cell lineage 
decisions with proliferation and differentiation and the 
subsequent migration of progenitors during neurogenesis 
among other functions[99]. These proteins share a bHLH 
domain enabling homo­ or heterodimerization upon 
DNA­binding to E­box (CANNTG) motives. Two major 
groups can be distinguished: the spatiotemporally 
expressed specification factors (e.g., NeuroD, neuro­
genin, Mash, and Math) and the ubiquitously expressed 
dimerization factors known as E­proteins. The latter 
group comprises the two splice variants of E2A, E12 
and E47, HEB, and TCF4 (also called E2-2)[100]. Among 
these genes, Tcf4 has been recently identified as direct 
Zac1 target gene during early neurogenesis[101]. Zac1 
recognizes multiple GC­rich DNA­elements at both the 
promoter and first intron of Tcf4 to confer synergistic 
transactivation as shown by reporter assays with various 
Tcf4 promoter reporter plasmids and Zac1 constructs. 
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Moreover, sequential ChIP assays corroborated that Zac1 
binding associates with the presence of active histone 
marks at Tcf4. 
Interestingly, E­proteins share with Zac1 a cell 
cycle arrest function, which has been attributed to 
their induction of p57Kip2 in neuroblastoma cells[102]. 
Compatible with these findings several predicted E-box 
motifs exist in the distal p57Kip2 promoter and confer 
Zac1 transactivation via Tcf4 upregulation[101]. 
Collectively, these data suggest that p57Kip2 is an 
indirect Zac1 target gene via transactivation of Tcf4. 
In this regard, a further investigation has pointed to 
a critical function of p57Kip2 in β­cell replication[103]. 
Hyperinsulinism of infancy presents a complex 
syndrome in which β­cells fail to suppress the secretion 
of insulin under hypoglycemic conditions[104]. The 
majority of patients suffer from mutations of either 
in KCNJ11 (encoding two subunits of the β­cell ATP­
sensitive K+ channel)[105] or ABCC8 (encoding a 
sulfonylurea receptor)[106], both of which regulate the 
secretion of insulin. 
Hyperinsulinism of infancy can be histologically 
distinguished into a diffuse form affecting all β­cells 
and a focal one in which a single cell population un­
dergoes clonal expansion. Genetically, focal β­cell 
hyperplasia results from a duplication of the p terminus 
of paternal chromosome 11 at the cost of the maternal 
allele. This recombination event results in two mutated 
alleles at the ABCC8/KCNJ11 loci and UPD for all genes 
telomeric to this site[107]. The duplicated segment 
harbors several paternally silenced imprinted genes 
including p57KIP2 whose expression is extinguished in 
mutated β­cell descendants[108]. To evidence a role in 
β­cell proliferation, shRNA was used to silence p57KIP2 in 
islets obtained from deceased donors free of pancreatic 
dysfunctions[103]. Interestingly, such p57KIP2 knock­down 
β­cells reassumed replication when transplanted under 
the kidney capsule of immunodeficient hyperglycemic 
mice and showed a normal glucose­induced calcium 
influx in support of an intact β­cell function. 
In sum, this study identifies biallelic silencing 
of p57Kip2 as a critical pathogenic factor for focal 
hyperinsulinism. Functionally, p57Kip2 seems to act as 
a gatekeeper of mature β­cell replication. In this res­
pect, ZAC1 overexpression in TNDM1 may upregulate 
p57KIP2 via TCF4 at crucial stages of prenatal and 
postnatal development. Transgenic ZAC1 mice provide 
a valuable model to explore this hypothesis in future 
studies. 
CONCLUSION
The steady rise of the diabetic epidemic makes further 
progress on the genetic, cellular, and physiological 
basis of this multifactorial disease mandatory. Accidents 
of nature leading to well­defined genetic defects 
can provide valuable insights into β­cell function 
and glucose metabolism in general. TNDM1, a rare 
monogenetic disease, appears of particular interest 
in this respect given its variable clinical course 
representing postnatally with severe hyperglycemia 
and insulin deficiency, remission within one and 
a half year, and frequent relapse with T2D in ad­
olescence. Identification of the genetic defects at 
chromosome 6q24 (UPD6, duplication of the TNDM1 
region, relaxation of genomic imprinting) point to 
altered dosage of monoallelically expressed ZAC1 as 
important pathogenic factor in TNDM1. Consistent with 
this view, ZAC1 overexpression in transgenic mice 
simulated major aspects of the human disease. A set 
of biochemical and molecular studies showed that 
Zac1 represents a zinc­finger protein with versatile 
regulatory functions dependent on DNA­binding to 
specific GC-rich motives and interconnected regulation 
of recruited coactivator activities. Additionally, Zac1 can 
serve as coactivator for the p53 and nuclear receptor 
families even so this function is presently largely 
unexplored with respect to TNDM1. Contrarily, the role 
as canonical transcription factor allowed gaining insight 
into ZAC1’s role in TNDM1 through the identification 
of downstream target genes. Genome­wide expres­
sion profiling enabled the isolation of a set of direct 
target genes known to regulate various aspects 
of β­cell function and peripheral insulin sensitivity. 
Among these, Zac1­dependent upregulation of the 
transcription factors Pparγ and Tcf4 may translate into 
an altered expression of downstream targets sharing a 
role in insulin secretion (Ucp-2) and β­cell proliferation 
(Pten and p57Kip2) (Figure 3, middle). Similarly, Zac1­
mediated transactivation of Socs3 may inhibit β­cell 
proliferation and survival by attenuating growth factor 
signaling. Moreover, altered ZAC1 dosage in TNDM1 
may also extend to SOCS3 upregulation in peripheral 
tissues and underlie impaired insulin signaling in 
relapsed patients with T2D (Figure 3, right).
Additionally, Zac1­dependent repression of down­
stream target genes may as well contribute to reduced 
insulin secretion and β­cell proliferation. In this regard, 
Pac1 and Rasgrf1 were repressed by Zac1 in β­cells, but 
not in neural cells, indicating that Zac1’s transcriptional 
or coregulatory activities are tissue­specific[42,53,59,61]. 
Pac1 enhances the insulin­secretory response to insulin, 
GSIS, and β­cell proliferation (Figure 3, left). Similarly, 
Rasgrf1 repression attenuated Ras­mediated activation 
of canonical and non­canonical pathways in GSIS. Even 
so, Zac1 overexpression in β­cells spared the effects of 
GPCR on GSIS. In any case, the concerted regulation of 
these target genes in β­cells and peripheral tissues may 
partly explain the clinical course of TNMD1 ranging from 
fatal neonatal hyperglycemia, subsequent remission, to 
adolescent relapse with T2D.   
Interestingly, relapsed TNDM1 patients show in 
response to both the oral and intravenous glucose 
tolerance test a subnormal insulin secretion, whilst 
glucagon­stimulated insulin secretion is preserved[87]. 
This raises the possibility that insulin secretion via 
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stimulatory G­protein signaling is maintained in TNDM1 
and thus partly restores β­cell function while being 
compromised for GSIS. Indeed, treatments targeting 
the GLP­1 pathway have been lately reported as 
an interesting therapeutic option instead of insulin 
substitution in relapsed TNDM1 patients[109]. This 
finding corroborates previous work in experimental 
diabetic mice, where liraglutide treatment ameliorated 
hyperglycemia following subcutaneous transplantation 
of either parent or Zac1 overexpressing β­cells[42]. 
Overall, these results demonstrate that elucidation 
of the molecular and cellular foundations of rare mo­
nogenetic diabetic diseases can substantially advance 
our understanding of β­cell function and glucose 
metabolism in general. The advent of precision me­
dicine[110] may not only offer access to personalized 
information we look for to stay healthy but may also 
lead to tailored treatments as suggested here for 
TNDM1 following ZAC1 overexpression.  
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